224 related articles for article (PubMed ID: 38115075)
1. Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis.
Yang JW; Zou Y; Chen J; Cui C; Song J; Yang MM; Gao J; Hu HQ; Xia LQ; Wang LM; Lv XY; Chen L; Hou XG
J Transl Med; 2023 Dec; 21(1):921. PubMed ID: 38115075
[TBL] [Abstract][Full Text] [Related]
2. Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation.
Yang M; Xia L; Song J; Hu H; Zang N; Yang J; Zou Y; Wang L; Zheng X; He Q; Liu J; Liu F; Liang K; Sun L; Chen L
Lipids Health Dis; 2023 Nov; 22(1):202. PubMed ID: 38001459
[TBL] [Abstract][Full Text] [Related]
3. Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway.
Zhang N; Liu T; Wang J; Xiao Y; Zhang Y; Dai J; Ma Z; Ma D
Drug Des Devel Ther; 2023; 17():3047-3060. PubMed ID: 37808345
[TBL] [Abstract][Full Text] [Related]
4. Didymin, a dietary citrus flavonoid exhibits anti-diabetic complications and promotes glucose uptake through the activation of PI3K/Akt signaling pathway in insulin-resistant HepG2 cells.
Ali MY; Zaib S; Rahman MM; Jannat S; Iqbal J; Park SK; Chang MS
Chem Biol Interact; 2019 May; 305():180-194. PubMed ID: 30928401
[TBL] [Abstract][Full Text] [Related]
5. Didymin protects pancreatic beta cells by enhancing mitochondrial function in high-fat diet-induced impaired glucose tolerance.
Yang J; Zou Y; Lv X; Chen J; Cui C; Song J; Yang M; Hu H; Gao J; Xia L; Wang L; Chen L; Hou X
Diabetol Metab Syndr; 2024 Jan; 16(1):7. PubMed ID: 38172956
[TBL] [Abstract][Full Text] [Related]
6. Didymin ameliorates dexamethasone-induced non-alcoholic fatty liver disease by inhibiting TLR4/NF-κB and PI3K/Akt pathways in C57BL/6J mice.
Feng Z; Pang L; Chen S; Pang X; Huang Y; Qiao Q; Wang Y; Vonglorkham S; Huang Q; Lin X; Wei J
Int Immunopharmacol; 2020 Nov; 88():107003. PubMed ID: 33182043
[TBL] [Abstract][Full Text] [Related]
7. [Effect of pure total flavonoids from citrus on hepatic SIRT1/PGC-1alpha pathway in mice with NASH].
Chen ZY; Li JS; Jiang JP; Yan MX; He BH
Zhongguo Zhong Yao Za Zhi; 2014 Jan; 39(1):100-5. PubMed ID: 24754177
[TBL] [Abstract][Full Text] [Related]
8. Didymin Alleviates Hepatic Fibrosis Through Inhibiting ERK and PI3K/Akt Pathways via Regulation of Raf Kinase Inhibitor Protein.
Lin X; Bai F; Nie J; Lu S; Lu C; Zhu X; Wei J; Lu Z; Huang Q
Cell Physiol Biochem; 2016; 40(6):1422-1432. PubMed ID: 27997902
[TBL] [Abstract][Full Text] [Related]
9. Si-Ni-San reduces lipid droplet deposition associated with decreased YAP1 in metabolic dysfunction-associated fatty liver disease.
Zheng K; Zhou W; Ji J; Xue Y; Liu Y; Li C; Zhang Z; Lu J; Shi X; Li Y
J Ethnopharmacol; 2023 Apr; 305():116081. PubMed ID: 36608777
[TBL] [Abstract][Full Text] [Related]
10. Didymin, a dietary flavonoid glycoside from citrus fruits, induces Fas-mediated apoptotic pathway in human non-small-cell lung cancer cells in vitro and in vivo.
Hung JY; Hsu YL; Ko YC; Tsai YM; Yang CJ; Huang MS; Kuo PL
Lung Cancer; 2010 Jun; 68(3):366-74. PubMed ID: 19733932
[TBL] [Abstract][Full Text] [Related]
11. Recent Trends in Potential Therapeutic Applications of the Dietary Flavonoid Didymin.
Yao Q; Lin MT; Zhu YD; Xu HL; Zhao YZ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30301216
[TBL] [Abstract][Full Text] [Related]
12.
Yu LP; Li YJ; Wang T; Tao YX; Zhang M; Gu W; Yu J; Yang XX
World J Gastroenterol; 2023 Jan; 29(1):171-189. PubMed ID: 36683716
[TBL] [Abstract][Full Text] [Related]
13. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
14. SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of resveratrol against neurodevelopment damage by fluoride.
Zhao Q; Tian Z; Zhou G; Niu Q; Chen J; Li P; Dong L; Xia T; Zhang S; Wang A
Theranostics; 2020; 10(11):4822-4838. PubMed ID: 32308752
[No Abstract] [Full Text] [Related]
15. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway.
Liao J; Xie X; Wang N; Wang Y; Zhao J; Chen F; Qu F; Wen W; Miao J; Cui H
Phytomedicine; 2024 Feb; 124():155285. PubMed ID: 38185065
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation.
Fang WJ; Wang CJ; He Y; Zhou YL; Peng XD; Liu SK
Acta Pharmacol Sin; 2018 Jan; 39(1):59-73. PubMed ID: 28770830
[TBL] [Abstract][Full Text] [Related]
17. Didymin Ameliorates Liver Fibrosis by Alleviating Endoplasmic Reticulum Stress and Glycerophospholipid Metabolism: Based on Transcriptomics and Metabolomics.
Li Y; Li C; Xiong Y; Fang B; Lin X; Huang Q
Drug Des Devel Ther; 2022; 16():1713-1729. PubMed ID: 35698653
[TBL] [Abstract][Full Text] [Related]
18. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
[TBL] [Abstract][Full Text] [Related]
19. Terf2ip deficiency accelerates non-alcoholic steatohepatitis through regulating lipophagy and fatty acid oxidation via Sirt1/AMPK pathway.
Wang Y; Liu S; Ni M; Chen Y; Chen R; Wang J; Jiang W; Zhou T; Fan S; Chang J; Xu X; Zhang Y; Yu Y; Li X; Li C
Free Radic Biol Med; 2024 Aug; 220():78-91. PubMed ID: 38697492
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
